p63基因在肺癌组织中的表达

目的研究肺鳞状细胞癌、腺癌、大细胞肺癌、小细胞肺癌以及淋巴结或肺内转移性肿瘤标本组织中p63基因的mRNA转录因子和蛋白表达水平,探讨p63基因表达与其定位在3q 27-q29区域改变的关系.方法采用cDNA微阵列技术同时检测72例不同病理组织学类型的原发性肺癌(包括鳞状细胞癌、腺癌、大细胞癌、小细胞癌)和肺癌肺内转移及淋巴结转移灶内的p63基因mRNA水平.另外,利用组织芯片技术构建150例原发性肺癌石蜡包埋标本组织芯片,采用免疫组织化学LSAB法检测p63基因蛋白表达情况.同时应用比较基因组杂交(CGH)技术对70例原发性肺癌标本进行了3号染色体长臂改变的分析.结果p63mRNA转录因子在肺鳞状细胞癌标本表达明显增强,与腺癌、大细胞癌、小细胞癌相比增多10倍以上.肺癌转移灶内p63基因mRNA表达水平明显高于其相对应的原发性灶,差异有统计学意义(P＜0.001).免疫组织化学染色结果显示肺鳞状细胞癌阳性表达率为94.64%;腺癌是1.79%;4例大细胞肺癌中2例为阳性染色;但所有小细胞肺癌标本免疫组织化学染色均为阴性.pT1分期肺癌的p63基因蛋白表达阳性率与pT2分期肺癌相比有统计学差异(P＜0.05).比较基因组杂交结果发现肺鳞状细胞癌3号染色体长臂27-29区域有显著的扩增,腺癌表现为缺失.鳞状细胞癌p63基因的表达增强与3q27-q29区域的显著扩增有明显正相关性(P＜0.000 1),说明定位于3号染色体长臂27-29区域的p63基因的拷贝有明显的扩增.结论p63mRNA转录因子和蛋白在肺鳞状细胞癌较其他肿瘤表达显著增高,转移灶高于原发灶;肺鳞癌p63表达增强与3号染色体长臂3q27-q29区域的扩增显著相关.     

p53、p21~(WAF1)蛋白在非小细胞肺癌中的表达及其临床意义

目的　探讨原发性非小细胞肺癌中p5 3、p2 1WAF1蛋白表达与临床病理及预后的关系。方法　应用免疫组织化学 (SP法 )方法。共检测非小细胞肺癌 147例 ,其中腺癌 6 6例 ,鳞癌 6 3例 ,腺鳞癌 14例 ,大细胞癌 4例。结果　p5 3蛋白总阳性率为 6 1.2 % (90 / 147) ,腺癌为 5 7.6 % (38/ 6 6 ) ,鳞癌阳性率为 6 3.5 % (4 0 / 6 3) ,腺鳞癌为 71.4% (10 / 14) ,大细胞癌 2例阳性。p2 1WAF1蛋白总阳性率为40 1% (5 9/ 147) ,腺癌为 42 .4% (2 8/ 6 6 ) ,鳞癌为 41.3% (2 6 / 6 3) ,腺鳞癌 2 8.6 % (4 / 14) ,大细胞癌 1例阳性。肺腺癌p5 3蛋白阳性表达与其预后相关 ,6 6例腺癌中 ,生存率低于 3年组和高于 3年组的p5 3蛋白阳性率分别为 75 % (2 1/ 2 8)和 44 .7% (17/ 38) ,差异有显著性意义 (P <0 .0 2 5 )。p2 1WAF1阳性表达与肺癌预后有关 ,p2 1WAF1阳性表达者 3年生存率 (6 4.4% )高于阴性表达者 (4 6 .6 % ) (P <0 .0 5 )。p5 3阳性而p2 1WAF1阴性的非小细胞肺癌患者的预后比p5 3阴性而p2 1WAF1阳性者差 (P <0 .0 1)。结论　检测p5 3蛋白表达可作为判断肺腺癌预后的指标之一 ;检测p2 1WAF1蛋白表达有利于对非小细胞肺癌预后的判断 ;联合检测p5 3、p2 1WAF1蛋白对判断非小细胞肺癌的预后有重要的意义 ,似可作     

联合检测TTF1、CK5/6、p63和napsinA在肺鳞癌和腺癌鉴别诊断中的价值

目的 探讨TTF1、CK5/6、p63和napsinA联合检测在肺鳞状细胞癌和腺癌鉴别诊断中的价值.方法 应用免疫组化EnVision法分别检测30例肺鳞状细胞癌和30例肺腺癌中TTF1、CK5/6、p63和napsinA的表达.结果 CK5/6、p63、TTF1和napsinA在肺鳞状细胞癌中的阳性率分别为96.7%、100%、20%和0,同时在肺腺癌中的阳性率分别为10%、20%、86.7%和90%.单个标志物中,CK5/6阳性和napsinA阴性对肺鳞状细胞癌与腺癌的鉴别诊断具有较高的特异性和敏感性;联合标志物检测中,p63和CK5/6共同表达阳性与TTF1和napsinA共同表达阴性在肺鳞状细胞癌的诊断中具有较高的特异性.结论 TTF1、CK5/6、p63和napsinA联合检测可鉴别肺鳞状细胞癌和腺癌,p63和CK5/6共同阳性表达与TTF1和napsinA共同阴性表达更加支持肺鳞状细胞癌,而非肺腺癌,反之亦然.     

肺癌中P63与P53、E-cadherin、Ki-67表达的比较

目的　比较 p6 3及 p5 3、E cadherin(E cad)、Ki 6 7在肺癌中的表达 ,以了解在不同组织类型肺癌发生发展过程中 ,p6 3与抑癌基因 (p5 3)突变、上皮分化标志基因 (E cad)失活及细胞增殖标志基因 (Ki 6 7)激活有无相关性。方法　采用免疫组化S P法分别检测 6 1例原发性肺癌中 p6 3、p5 3、E cad和Ki 6 7的表达情况。 结果　p6 3在肺鳞癌中阳性率为 10 0 0 % ,而在其他组织类型肺癌中 p6 3基本不表达 ,差异有显著性 (P <0 0 5 ) ;在不同分化程度的肺鳞癌中 p6 3、p5 3的表达差异有显著性 (P<0 0 5 ) ,E cad、Ki 6 7的表达差异无显著性 (P >0 0 5 ) ;E cad的表达在小细胞肺癌与肺鳞癌和肺腺癌之间差异有显著性 (P <0 0 5 ) ;Ki 6 7的表达在各种组织类型肺癌之间差异有显著性 (P <0 0 5 ) ;在不同分化程度鳞癌中 p6 3与E cad的表达呈负相关(P <0 0 5 )。结论　p6 3可作为鳞状上皮源性肿瘤标记物 ,是判断鳞状细胞癌的增殖和分化有意义的指标 ,并可作为鉴别分化差的鳞癌和腺癌、小细胞癌的指标。     

应用组织芯片研究p63及其同系物在肺癌中的表达

目的研究p63蛋白及其同系物TAp63、△Np63在肺癌组织中的表达,并初步探讨其生物学意义。方法选取183例肺癌、30例肺良性病变的石蜡标本,应用组织芯片技术和免疫组织化学方法观察三种蛋白在肺良、恶性病变中的表达情况。结果p63蛋白及其同系物map63、△Np63三者在肺鳞状细胞癌、腺癌、细支气管肺泡癌、小细胞癌的表达具有一致性（r〉0．75,P〈0．01）,且在鳞状细胞癌中的表达率均高于其它类型（P〈0．01）;在鳞状细胞癌中△Np63表达率（74．6％）略高于map63（67．2％）,但无统计学意义（P〉0．05）。三种蛋白的表达与患者性别、年龄、肿瘤分化程度、肿瘤大小、有无淋巴结转移及临床分期不相关（P〉0．05）。p63、TAp63及△Np63在肺癌旁组织或肺良性病变的肺泡上皮细胞和支气管纤毛柱状上皮不表达,而只表达于支气管上皮的基底细胞和支气管腺的肌上皮细胞。结论p63基因在不同类型的肺癌中作用不同,在鳞状细胞癌的发生发展中起着重要的作用。两种同系物map63和△Np63在鳞状细胞癌中也呈高表达,其机制有待研究。p63可作为肺鳞状细胞癌与其它类型癌鉴别的重要依据。     

声门上喉癌的染色体异常和重要相关基因的研究

目的筛查声门上喉癌发生、发展及转移相关的异常染色体和重要基因。方法应用比较基因组杂交（comparative genomic hybridization，CGH）分析喉声门上鳞状细胞癌（laryngeal squamous cell cancer，LSCC）癌组织和癌旁组织DNA拷贝数的差异。应用cDNA芯片结合聚类分析研究喉声门上癌癌旁组织、癌组织和转移淋巴组织中差异表达的基因。结果CGH结果表明每例喉癌平均涉及12．9个染色体的异常，其中出现高频率扩增的染色体区集中在3q15-21（14／18）、5p12-13（11／18）、8q22-24（6／18）、11q12-13（8／18）、15q21-23（7／18）and 18p11（8／18），而高频率缺失的染色体区集中在1p13-21（8／18）、3p21-23（14／18）、5q21-22（14／18）、9p12-pter（11／18）and 13q21—31（8／18）。聚类分析将表达差异的基因分为3组。表达差异在5倍以上的基因12个，在由癌旁至癌阶段、癌至转移阶段均存在表达异常的基因3个。这15个重要基因是喉癌新的相关基因，其中4个基因cytoehrome C oxidase Va，PPBP，EPHX2 and PONI与喉癌相关性的研究未见报道，而且，SH3GL2位于高频率缺失的染色体区9p12-pter。结论我们发现的特异染色体区和重要基因将为喉癌发生、发展和转移的研究提供重要线索。     

出现于三例肺腺癌中的等臂染色体i(8q)或i(9q)

本文所分析的9例肺腺癌,6例来自细胞系,3例来自转移物,对3例原发性肺腺癌,用G显带技术进行了细胞遗传学研究。例1仅分析了6个异常中期相,多数质量很差。其染色体数是68～75。发现了两个衍生的1号染色体,均含有来源不清的片段;其中一个染色体在p34处增加了数条深带,另一个染色体在p11处增加了数条深带。3 p十标记染色体的断裂点是3 p23或3 p24。有1个i(6p)和2个i(8q)。在7 p+,11q+,15p+和17p+标记染色体(断裂点7 p22, 11q25,     

用显微切割技术定点检测诱发大鼠肺癌发生发展各阶段p53、K-ras基因突变与表达

目的　探讨p5 3、K ras基因突变、蛋白表达在 3 甲基胆蒽 (3 methylcholanthrene ,MCA)和二乙基亚硝胺 (diethylinitrosamine ,DEN)诱发大鼠肺鳞癌发生演进中的作用 ,及其突变与蛋白表达的关系。方法　将大鼠诱发肺癌石蜡标本连续切片 ,切片用于HE染色确定肺癌发生发展的病变阶段 ,及免疫组织化学 (SP法 )检测各阶段p5 3、K ras蛋白表达 ,并用于显微切割 ,定点对位分别切割由正常支气管黏膜上皮细胞演变成癌细胞 ,癌浸润、转移各阶段病灶的主质 ,提取DNA ,用聚合酶链反应 单链构象多态性 (PCR SSCP)检测各阶段p5 3、K ras基因的突变。结果　 30例正常支气管黏膜上皮未检测到p5 3、K ras基因突变及其蛋白表达。在 32例支气管黏膜增生和鳞状化生、2 1例不典型增生、12例原位癌、4 3例浸润癌及 17例转移癌组织中 ,p5 3基因突变率分别为 3 1% ,2 8 6 % ,30 0 % ,5 1 2 % ,5 2 9% ;p5 3蛋白阳性表达率分别为 0 ,4 2 9% ,5 0 0 % ,6 0 5 % ,6 4 7% ;不典型增生阶段与增生、鳞状化生阶段相比 ,p5 3基因突变率及蛋白表达率增高 ,差异均有显著性意义 (P <0 0 2 5 ,P <0 0 0 5 ) ,p5 3基因突变及蛋白阳性表达高度相关 (P <0 0 0 5 ,Pearson′sR =0 5 996 )。K ras基因突变率分别为 0 ,4 8% ,8 3% ,9 3     

髓母细胞瘤比较基因组杂交分析及ERBB-2异常表达的意义

目的研究髓母细胞瘤全基因组的遗传学异常,探讨癌基因的异常表达在髓母细胞瘤发病机制中的作用以及与预后的关系。方法应用比较基因组杂交（comparative genomic hybridization,CGH）技术检测14例髓母细胞瘤全基因组的遗传学改变;同时,在扩大系列的29例髓母细胞瘤中,应用荧光原位杂交（fluorescence in situ hybridization,FISH）和免疫组化染色分别检测ERBB-2在基因水平和蛋白水平的表达。结果（1）CGH结果显示,在所有14例髓母细胞瘤标本中,每一条染色体臂上都检测到了染色体的失衡（获得或丢失）,最常见的染色体异常为17q（85．7％）和7q（35．7％）的获得,以及8p（50％）、16q（28．6％）和17p（35．7％）的丢失;（2）FISH检测中,44．5％（13／29例）的肿瘤细胞有ERBB-2基因的异常表达;（3）免疫组化结果显示,37．9％（11／29例）的病例有抗体c-erbB-2的阳性表达;（4）在预后较差的16例患者中,56％（9／16例）的病例有ERBB-2的过度表达。结论CGH研究发现了髓母细胞瘤全基因组的染色体失衡。在染色体17q特异性位点上ERBB-2基因的异常改变很可能在髓母细胞瘤的发病机制中起着重要的作用,其过度表达与患者的预后密切相关。     

肺鳞状细胞癌中死亡相关蛋白激酶的表达

目的　检测肺鳞状细胞癌中死亡相关蛋白激酶 (DAP K)mRNA表达及细胞凋亡 ,探讨DAP K与细胞凋亡的关系及其在肺鳞状细胞癌发生、发展中的作用。方法　用原位分子杂交法检测 6 0例肺鳞状细胞癌、9例癌旁肺组织DAP KmRNA表达 ;用原位末端标记TUNEL法检测相应组织中细胞凋亡 ,计算凋亡指数 (AI)。结果　肺鳞状细胞癌的DAP KmRNA阳性表达率为 4 6 7% ,癌旁肺组织为 6 7 7% ,其阳性率高于肿瘤组织 (P <0 0 1 )。在肺鳞状细胞癌中 ,高分化癌DAP KmRNA阳性率为 70 % ,低分化癌为 2 3 3% ,高分化癌的DAP KmRNA阳性率高于低分化癌 (P <0 0 1 )。肺鳞状细胞癌的细胞AI为(0 6 72 8± 0 4 2 6 1 ) % ,癌旁肺组织中支气管肺泡上皮细胞AI为 (1 0 2 89± 0 2 4 33) % ,癌旁肺组织的AI高于肿瘤组织 (P<0 0 1 )。在肺鳞状细胞癌中 ,高分化癌的AI为 (0 5 82 3± 0 1 92 2 ) % ,低分化癌为 (0 4 4 6 0± 0 1 92 5 ) % ,高分化癌的AI高于低分化癌 (P <0 0 1 )。DAP KmRNA呈阳性表达的肺癌 ,其AI为 (0 5 31 7± 0 2 0 97) % ;DAP KmRNA呈阴性者 ,其AI为 (0 4 872± 0 1 91 8) % ,两组间差异有显著性 (P <0 0 5 )。在连续切片上 ,DAP KmRNA阳性细胞的分布区域与凋亡阳性细胞的分布相似。DAP KmRNA呈阳性表达     

p63 expression in adamantinoma

Paratesticular fibrous pseudotumor (nodular periorchitis, inflammatory pseudotumor of the spermatic cord) is a rare, benign condition of unknown etiology characterized by solitary or multiple intrascrotal nodules composed of dense fibrous tissue with a variable, sometimes sparse inflammatory infiltrate. Based on certain similarities to other fibroinflammatory disorders characterized by infiltrates of IgG4-expressing plasma cells and recently subsumed under the heading of IgG4-mediated diseases, we investigated the plasma cell distribution and immunoglobulin isotypes in three cases of paratesticular fibrous and inflammatory pseudotumor. All three cases showed a high number of IgG4-positive plasma cells with an IgG4 to IgG ratio of 44–48%. This finding indicates that paratesticular fibrous pseudotumor might belong to the growing list of IgG4-related diseases, which by now includes such diverse entities as retroperitoneal fibrosis, sclerosing pancreatitis and cholangitis, Riedel’s thyroiditis, or sclerosing sialadenitis.     

Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry

The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of an N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have extensively characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. Twenty-eight of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. Phage display revealed that the PANp63-6.1 epitope has one amino acid difference between p63 and p73, the 4A4 epitope is identical in both, whereas the SFI-6 epitope is unique to p63, accounting for these findings. We also produced and characterized a TAp63-specific clone that does not recognize p53 or p73, and we prepared polyclonal sera specific for ΔNp63 isoforms. Immunohistochemistry demonstrated that TAp63 is expressed in a variety of epithelial and other cell types during development, often in a converse pattern to ΔNp63, but has a very limited expression in normal adult tissues and is independent of ΔNp63. TAp63 was expressed in 17.6 % of squamous cancers of cervix that expressed p63, unlike normal cervix where TAp63 was not expressed. TAp63 did not associate with proliferative index, but cervical carcinomas with TAp63 expression showed improved survival. These data highlight the need for rigorous antibody characterization and indicate that p63-isoform identification may improve the clinical value of p63 expression analyses.     

Naked nuclei revisited: p63 Immunoexpression

The presence of naked nuclei (NN) in cytological preparations of fibroadenomas is a well-known finding. Regardless of their importance on the differential diagnosis of fibroadenoma and other benign lesions of the breast, the origin of NN remains elusive. Despite previous efforts to characterize them, the lack of a reliable nuclear marker for myoepithelial cells impaired definitive conclusions. We performed a systematic evaluation of p63 expression in cytological and histological preparations of 10 fibroadenoma specimens. We observed that in histological sections, p63 was restricted to the nuclei of myoepithelial/basal cells in lobules and ducts of normal breast. In fibroadenomas, p63 decorated the nuclei of myoepithelial cells in the periphery of epithelial duct-like formations and slit-like formations. No p63 immunoreactivity was observed in stromal or epithelial cells. In cytological samples, almost all NN and cells surrounding epithelial cell clusters were stained; no stromal cell admixed with fibrillary matrix or epithelial cell was stained with p63. Based on our findings, we strongly suggest that most, if not all, NN are myoepithelial in origin.     

p53、p63及p73在皮肤血管瘤组织中的表达

目的　为探讨p5 3p6 3及p73蛋白在皮肤血管瘤组织中的表达及意义。方法　采用免疫组织化学S P法和图像分析技术检测 4 0例血管瘤组织和 2 0例正常皮肤组织中p5 3、p6 3及p73基因的表达。结果　在增生期血管瘤、退化期血管瘤和正常皮肤组之间 ,p73蛋白免疫组化阳性反应颗粒的平均光密度分别为 6 4 0 8± 2 15 1、1 0 73± 0 5 16和 0 95 3± 0 12 0。p6 3蛋白免疫组化阳性反应颗粒的平均光密度分别为 8 2 71± 1 95 3、0 92 3± 0 191和 0 92 0± 0 187。p5 3蛋白免疫组化阳性反应颗粒的平均光密度分别为 7 2 4 0± 1 874、0 934± 0 187和 0 92 3± 0 16 5。增生期血管瘤与退化期血管瘤、正常皮肤组分别组比 ,p73、p6 3及p5 3阳性表达的差异均有高度显著性差异 (P <0 0 0 1) ,消退期血管瘤与正常皮肤组之间 ,p73、p6 3及p5 3阳性表达差异无显著性 (P >0 0 5 )。结论　在增生期血管瘤组织中p73、p6 3及p5 3呈高表达 ,促进了内皮细胞的增殖 ,是导致血管瘤发生、发展的主要因素     

Expression of p63 in cutaneous metastases

p63 is an oncogene belonging to the p53 gene family. In normal human skin, p63 is expressed by the least-differentiated keratinocytes of the epidermis and its appendages, by myoepithelial cells of sweat glands, and by a wide variety of primary tumors arising therefrom. The expression of p63 by metastatic skin tumors has been more controversial. In this study, we assessed the usefulness of p63 detection in the differential diagnosis between primary and secondary (metastatic) skin tumors. The expression of p63 was studied in 45 cases of cutaneous metastases, mostly of known primary origin, and 94 benign and malignant epithelial primary skin tumors. p63 was expressed by 85 (89%) of 96 primary skin tumors and 5 (11%) of 45 cutaneous metastases. These results suggest that p63 may be a useful adjunct in the diagnosis of skin carcinomas; however, contrary to what has been previously claimed, expression of p63 does not rule out the metastatic origin of a cutaneous carcinoma.     

The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis

p63, a member of the p53 gene family, is known to encode functionally antagonistic protein isoforms. Although transactivating protein isoforms display p53-like functions, deltaNp63 isoforms act toward p53 in a dominant negative way. Using immunohistochemistry, we examined the expression of pan-p63 and deltaNp63 in 50 esophageal squamous cell carcinomas (SCCs) as well as in squamous low-grade intraepithelial neoplasias (S-LGINs; n = 4) and high-grade intraepithelial neoplasias (S-HGINs; n = 18). Additionally, 50 esophageal adenocarcinomas (ADCs) that arose in Barrett's esophagus (BE) as well as adjacent specialized metaplastic epithelium (SE; n = 41), low-grade intraepithelial neoplasias (B-LGINs; n = 27), and high-grade intraepithelial neoplasias (B-HGINs; n = 21) in BE were investigated. Furthermore, p63 gene amplification was determined by fluorescent differential polymerase chain reaction in a subset of 10 SCCs and 10 ADCs. Whereas in normal esophageal epithelium, expression of pan-p63 is invariably restricted to the basal cell layer, in 100% of S-LGINs, 94.4% of S-HGINs, and 88.0% of SCCs, expression of p63 was found in >75% of the cells. Concerning BE, only in a small subset of SEs (7.3%), B-LGINs (14.8%), B-HGINs (14.3%) and ADCs (16.0%) was a weak p63 protein expression (<10% positive cells) detectable, whereas the rest of the samples were completely negative. Expression of deltaNp63 was identical to expression of pan-p63 in the vast majority of samples. p63 gene amplification was found in 2 of 10 (20.0%) investigated SCCs and in 1 of 10 (10.0%) ADCs. In summary, strong expression of p63, especially its deltaNp63 isoforms, is a frequent finding in esophageal precancerous and cancerous squamous lesions, whereas this is not the case in carcinogenesis of BE. p63 gene amplification is an infrequent finding in esophageal SCCs and ADCs and does not correlate with protein overexpression.     

乳腺增生性病变中p63蛋白的表达及意义

目的 探讨p63蛋白在乳腺疾病诊断以及鉴别诊断中的应用价值。方法 对38例不同类型的乳腺病变分别进行p63、SMA、S-100蛋白、CK(34βE12)免疫标记。结果 p63蛋白在乳腺良性增生性病变腺体肌上皮细胞核有阳性表达,围绕在腺体周围,原位癌癌巢周围肌上皮细胞数目减少,呈间断性分布,浸润性癌癌巢周围肌上皮细胞大部分消失或无肌上皮细胞分布,且阳性表达强度与肿瘤分化程度相关。其他基底细胞标记物也可以比较特异地显示乳腺腺体周围肌上皮,但存在一定的非特异性着色。结论 从乳腺正常组织、良性病变至原位癌、早期浸润和浸润性癌,腺体周围的肌上皮细胞呈逐渐消失的趋势,p63蛋白标记可以比较特异地反映这个过程,而且受其他影响因素小。     

p63亚型及其与疾病的相关性

p63是p53家族成员的核转录因子,根据N端及C端的不同,已经发现TAp63α、TAp63β、TAp63γ、ΔNp63α、ΔNp63β、ΔNp63γ、ΔNp63δ、ΔNp63ε 8种亚型.p63的表达受到多种转录因子的调控,其mRNA的稳定性由RNPC1调节,蛋白的稳定性主要由HECT 家族成员Itch/AIP4、WW...